NCT07201051View on ClinicalTrials.gov

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

September 26, 2025

Primary Completion Date

March 15, 2027

Study Completion Date

November 8, 2027

Conditions

Bronchiectasis

Interventions

DRUG

GSK3862995B

Participants will be administered with dose level 1 of GSK3862995B.

DRUG

Placebo

Participants will be administered with matching placebo.

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY